Investigational drug · Phase 2
VOY-101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Age-Related Macular Degeneration, Geographic Atrophy, Non-neovascular AMD.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "VOY-101"
First trial start
2023
Jun 21, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VOY-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Age-Related Macular Degeneration
- Geographic Atrophy
- Non-neovascular AMD
- Non-neovascular Age-related Macular Degeneration
Approved drugs for the same conditions: Wet macular degeneration · Geographic atrophy · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "VOY-101" as an intervention, largest first.
- Long-Term Follow Up of VOY-101 Non-nAMD Extension StudyEnrolling by invitation
Perceive Biotherapeutics, Inc.Industry
NCT07660640 · 88 participants (planned) · Start Mar 3, 2026 · Primary completion Jul 30, 2031
Drug: VOY-101 · For: Age-Related Macular Degeneration (AMD); Non-Neovascular Age-Related Macular Degeneration
Sites: Boston, Massachusetts; Bellaire, Texas; Salt Lake City, Utah · 4 sites in all
- Phase 1/2 Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular DegenerationActive, not recruiting
Perceive Biotherapeutics, Inc.Industry
NCT06087458 · 60 participants (planned) · Start Jun 21, 2023 · Primary completion Oct 2027
Drug: VOY-101 · For: Age-Related Macular Degeneration; Geographic Atrophy; Non-neovascular AMD and 1 more
Sites: Scottsdale, Arizona; Poway, California; Sacramento, California · 16 sites in all
- Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular DegenerationStatus unknown
Perceive Biotherapeutics, Inc.Industry
NCT05380492 · 45 participants (planned) · Start Nov 17, 2022 · Primary completion Nov 2025
Drug: VOY-101 · For: Age-related Macular Degeneration; Geographic Atrophy
Sites: Boston, Massachusetts; Bellaire, Texas; Salt Lake City, Utah
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Age-Related Macular Degeneration
- TiespectusEYE201, MK-8748Phase 35 trials
EyeBiotech Ltd. · Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization
- OpRegenPhase 22 trials
Roche (Genentech) · Age-Related Macular Degeneration, Geographic Atrophy
- ABBV-6628Phase 21 trial
AbbVie · Geographic Atrophy, Age-Related Macular Degeneration
- KH631Phase 21 trial
Chengdu Origen Biotechnology Co., Ltd. · Age-Related Macular Degeneration
- KH658Phase 21 trial
Chengdu Origen Biotechnology Co., Ltd. · Age-related Macular Degeneration
- SOM-401Phase 21 trial
Inflammasome Therapeutics · Geographic Atrophy, Age-Related Macular Degeneration
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.